Patel, S., Milhem, M., Hallmeyer, S., Daniels, G., Cranmer, L., Taback, B., . . . Sharfman, W. (2014). Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin(® )(HD IL-2) and Ipilimumab Yervoy(® )) in patients with metastatic melanoma (proclivity 02). J Immunother Cancer.
Chicago-стиль цитированияPatel, Sapna, et al. "Open-label, Randomized, Multi-center Study Comparing the Sequence of High Dose Aldesleukin (Proleukin(® )(HD IL-2) and Ipilimumab Yervoy(® )) in Patients With Metastatic Melanoma (proclivity 02)." J Immunother Cancer 2014.
MLA-цитированиеPatel, Sapna, et al. "Open-label, Randomized, Multi-center Study Comparing the Sequence of High Dose Aldesleukin (Proleukin(® )(HD IL-2) and Ipilimumab Yervoy(® )) in Patients With Metastatic Melanoma (proclivity 02)." J Immunother Cancer 2014.